Kymera Therapeutics (KYMR) CEO reports 2,595-share stock option exercise

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. reported an insider stock option exercise by its Chief Executive Officer and director on 12/17/2025. The CEO exercised a stock option to acquire 2,595 shares of common stock at an exercise price of $38.53 per share. Following this transaction, he beneficially owns 663,077 shares of common stock directly.

The exercised option was a stock option (right to buy) covering 2,595 shares of common stock, with an exercise price of $38.53 and an expiration date of 03/01/2032. After the transaction, 272,505 derivative securities (stock options) remain beneficially owned directly. The filing notes that the shares underlying this stock option are fully vested and exercisable.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mainolfi Nello

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/17/2025		M		2,595	A	$38.53	663,077	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$38.53	12/17/2025		M			2,595	(1)	03/01/2032	Common Stock	2,595	$0	272,505	D

Explanation of Responses:

1. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	12/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report in this filing?

The filing reports that the Chief Executive Officer and director of Kymera Therapeutics, Inc. exercised a stock option on 12/17/2025 to acquire 2,595 shares of common stock at an exercise price of $38.53 per share.

How many Kymera Therapeutics (KYMR) shares does the CEO own after the reported transaction?

After the reported transaction, the CEO beneficially owns 663,077 shares of Kymera Therapeutics common stock directly, as stated in Table I of the filing.

What type of derivative security was involved in the Kymera Therapeutics (KYMR) insider transaction?

The transaction involved a stock option (right to buy) with an exercise price of $38.53, covering 2,595 shares of Kymera Therapeutics common stock.

When does the stock option in the Kymera Therapeutics (KYMR) Form 4 expire?

The stock option exercised in this transaction has an expiration date of 03/01/2032, as disclosed in Table II.

Are the Kymera Therapeutics (KYMR) stock options reported in this filing vested?

Yes. The explanation section states that the shares underlying this stock option are fully vested and exercisable.

How many Kymera Therapeutics (KYMR) stock options does the CEO still hold after exercising some options?

After the reported exercise, the CEO beneficially owns 272,505 derivative securities (stock options) directly, according to Table II.